Begin Main Content Area

​​​​​Neonatal Abstinence Syndrome Program

In 2018, Neonatal Abstinence Syndrome (NAS) became a reportable condition under PA code Title 28, Chapter 27 when the opioid epidemic was declared a statewide disaster emergency. The emergency declaration has since expired, but NAS remains a reportable condition under existing Department authority.

Pennsylvania utilizes the Council of State and Territorial Epidemiologist's (CSTE) case definition for NAS to define specific criteria for reporting. Hospitals and birthing facilities are advised to report all confirmed NAS cases in babies up to 28 days after birth that are showing symptoms of withdrawal due to prenatal exposure to opioids, benzodiazepines, or barbiturates via prescription, medication for opioid use disorder (MOUD) or illegal use. The purpose of this surveillance initiative is to acquire deidentified aggregate data to:

  • Describe burden of NAS in Pennsylvania;
  • Identify high incidence areas for the purpose of targeted intervention; and
  • Reduce statewide incidence rates of NAS.

Infants diagnosed with NAS may be eligible for special services. Every infant diagnosed with NAS is eligible for, at minimum, Early Intervention At-Risk Tracking. NAS reporting to the Department of Health does not constitute a referral to any other agency. Hospitals and birthing centers should continue to make appropriate notifications or referrals to other agencies as required.

Resources

Neonatal Abstinence Syndrome Family Guide Tool Kit: The Division of Newborn Screening and Genetics is excited to announce a new resource for infants and families impacted by Neonatal Abstinence Syndrome (NAS). Copies of the Neonatal Abstinence Syndrome Family Guide Tool Kit can be requested by contacting the Division of Newborn Screening and Genetics at 717-783-8143.

NAS Fact Sheet for Submitters: The NAS Fact Sheet is a helpful document, which outlines reporting standards and provides guidance to submitters regarding commonly asked questions.

Reports